M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
A bstract: A cholinergic hypofunction in Alzheimer's disease (AD) may lead to formation of β‐amyloids that might impair the coupling of M1 muscarinic ACh receptors (mAChRs) with G proteins. This disruption in coupling can lead to decreased signal transduction, to a reduction in levels of trophic amyloid precursor proteins (APPs), and to generation of more β‐amyloids that can also suppress ACh synthesis and release, aggravating further the cholinergic deficiency. These “vicious cycles,” a presynaptic and a postsynaptic one, may be inhibited, in principle, by M1 selective agonists. Such properties can be detected in the functionally selective M1 agonists from the AF series [e.g., project drugs, AF102B, AF150(S)]. These M1 agonists promote the nonamyloidogenic APP processing pathways and decrease tau protein phosphorylation. The effects on tau proteins suggest a link between M1 mAChR‐mediated signal transduction system(s) and the neuronal cytoskeleton via regulation of phosphorylation of tau microtubule‐associated protein. This may indicate a dual role for M1 agonists: as inhibitors of two “vicious cycles,” one induced by β‐amyloids, and the other due to overactivation of certain kinases (e.g., glycogen synthase kinase‐3, GSK‐3) or downregulation of phosphatases, respectively. Prolonged administration of AF150(S) in apolipoprotein E‐knockout mice restored cognitive impairments, cholinergic hypofunction, and tau hyperphosphorylation, and unveiled a high‐affinity binding site to M1 mAChRs. Except M1 agonists, there are no reports of compounds having such combined effects, for example, amelioration of cognition dysfunction and beneficial modulation of APPs together with tau phosphorylation. This unique property of M1 agonists to alter different aspects of AD pathogenesis could represent the most remarkable, yet unexplored, clinical value of such compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nitsch, R. M., Slack, B. E., Wurtman, R. J., & Growdon, J. H. (1992) · Science · doi:10.1126/science.1411529 · Cited by 898
Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester
Savage, M. J., Trusko, S. P., Howland, D. S., Pinsker, L. R., Mistretta, S., Reaume, A. G., Greenberg, B. D., Siman, R., & Scott, R. W. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-05-01743.1998 · Cited by 213
Cited by
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10011 · Cited by 333
Neuroplasticity in Alzheimer's disease
Teter, B., & Ashford, J. W. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10441 · Cited by 170
Zhong, P., Gu, Z., Wang, X., Jiang, H., Feng, J., & Yan, Z. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302789200 · Cited by 71
Metadata
- Authors
- FISHER, A., MICHAELSON, D. M., BRANDEIS, R., HARING, R., CHAPMAN, S., & PITTEL, Z.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2000-12
- Volume
- 920
- Issue
- 1
- Pages
- 315-320
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2090237566
- Cited by
- 62
- References
- 2
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives. https://app.cochat.ai/papers/10.1111/j.1749-6632.2000.tb06941.x
- The paper
- FISHER, A., MICHAELSON, D. M., BRANDEIS, R., HARING, R., CHAPMAN, S., & PITTEL, Z. (2000). M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and Perspectives. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2000.tb06941.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.